Sign In To Continue
You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
Enlivex Ltd. has obtained an Australian patent protecting the use of its immunotherapy Allocetra™ for treating osteoarthritis, extending intellectual property coverage until at least 2040. This milestone complements ongoing Phase 2b clinical trials targeting moderate-to-severe knee osteoarthritis, underscoring Enlivex…
Share This Article
Ready-to-post copy includes the article link.
Enlivex Secures Australian Patent for Allocetra™ in Osteoarthritis Treatment Through 2040 Enlivex Ltd. has obtained an Australian patent protecting the use of its immunotherapy Allocetra™ for treating osteoarthritis, extending intellectual property coverage until at least 2040. This milestone complements ong... Read the full IIPLA article: https://iipla.org/news/enlivex-secures-australian-patent-for-allocetra-in-osteoarthritis-treatment-through-2040